Endocrine therapy: is the first generation of targeted drugs the last?
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Endocrine therapy: is the first generation of targeted drugs the last?
Authors
Keywords
-
Journal
JOURNAL OF INTERNAL MEDICINE
Volume 274, Issue 2, Pages 144-152
Publisher
Wiley
Online
2013-07-12
DOI
10.1111/joim.12065
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Expression of both Estrogen Receptor-beta 1 (ER-β1) and its co-regulator Steroid Receptor RNA Activator Protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with Estrogen Receptor-alpha (ER-α)-Negative Early Breast Cancer (EBC)
- (2013) Y. Yan et al. ANNALS OF ONCOLOGY
- FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer
- (2012) Jonas Bergh et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
- (2012) Thomas Bachelot et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
- (2012) Linda Sofie Lindström et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
- (2012) Rita S. Mehta et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intratumor Heterogeneity: Seeing the Wood for the Trees
- (2012) T. A. Yap et al. Science Translational Medicine
- 5005 ORAL Exploratory Subgroup Analysis of the TAMRAD Phase 2 GINECO Trial Comparing Tamoxifen (TAM) Plus Everolimus (RAD) With TAM Alone in Patients With Hormone-receptor-positive, HER2-negative Metastatic Breast Cancer (mBC) With Prior Exposure to Aromatase Inhibitors (Als): Implication for Research Strategies
- (2011) C. Bourqier et al. EUROPEAN JOURNAL OF CANCER
- Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer
- (2011) Eitan Amir et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- The protein encoded by the functional steroid receptor RNA activator is a new modulator of ER alpha transcriptional activity
- (2010) Shilpa Chooniedass-Kothari et al. FEBS LETTERS
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
- (2009) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- ERβ in breast cancer—Onlooker, passive player, or active protector?
- (2008) Emily M. Fox et al. STEROIDS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started